Ensemble Classification and Cancer-Specific Gene Signatures from Quality-Aware Hybrid Gene Selection in TCGA RNA-Seq data
Organizations: Department of Computer Science and Engineering, Islamic University of Technology, Gazipur 1704, Bangladesh
Abstract
Gene-expression classifiers of cancer type are usually developed and validated within one cohort using random splits. Starting from a quality-aware hybrid Boruta selector from earlier work, we developed and evaluated ensemble classifiers and cancer-specific gene signatures. Using 10,469 TCGA tumours of 33 types, we compared five learners and three ensembles under decision rules fixed in advance, reran the selection in site-grouped cross-validation, transferred a breast-cancer subtype panel to 3273 tumours of the independent SCAN-B cohort, and built five-gene stageI tumour versus adjacent-normal panels for nine cancer types. Logistic regression (LR) was the most accurate and best-calibrated single learner (balanced accuracy 0.943 on the locked test set). Stacking added at most 0.006 with 1000 genes but improved on LR in every fold with a minimal 100-gene panel; a hierarchical model did not reduce within-group confusion. Site-grouped validation lowered balanced accuracy by 0.027, almost entirely in colon and rectal cancer (0.008 without them and the untestable LAML). On SCAN-B, the subtype panel reached 0.855, close to the 50 PAM50 genes (0.876). StageI panels reached ROC AUC >= 0.99 in held-out patients and detected most later-stage tumours. Ensembles help most with a minimal panel; with 1000 genes, a calibrated linear model suffices.
Figures & tables
| Task | Training data | Evaluation | Classes | Section |
|---|---|---|---|---|
| Cancer type | TCGA development, 8374 tumours | 5-fold CV; locked test set (2095) | 33 | 2.3 , 2.4 |
| Breast cancer subtype | TCGA-BRCA development, 797 tumours | SCAN-B (GSE96058), 3273 tumours | 5 (PAM50) | 2.5 |
| Stage I vs. adjacent normal | 9 TCGA types, development patients | patient-grouped CV; held-out patients | 2 per type | 2.6 |
| Model | CV, | CV, | Test, | Test log loss | Test ECE |
|---|---|---|---|---|---|
| Logistic regression (reference) | 0.947 0.011 | 0.930 | 0.943 (0.927–0.958) | 0.126 | 0.007 |
| Linear SVM | 0.940 0.012 | 0.890 | 0.928 (0.911–0.944) | 0.180 | 0.046 |
| MLP | 0.933 0.008 | 0.904 | 0.936 (0.919–0.952) | 0.149 | 0.018 |
| LightGBM | 0.941 0.014 | 0.916 | 0.928 (0.912–0.945) | 0.197 | 0.027 |
| Random forest | 0.905 0.018 | 0.890 | 0.893 (0.876–0.911) | 0.287 | 0.109 |
| Soft voting | 0.946 0.010 | 0.922 | 0.937 (0.921–0.952) | 0.145 | 0.039 |
| Type | Dev. | Selector | Panel (rank order) | CV AUC | Held-out AUC | Sens. | Spec. |
|---|---|---|---|---|---|---|---|
| BRCA | 148/94 | DE | COL10A1, MMP11, COL11A1, HSD17B6, LINC01614 | 0.996 | 0.994 | 23/26 | 19/19 |
| COAD | 49/33 | DE | FOXQ1, ETV4, KRT80, CDH3, SIM2 | 1.000 | 1.000 | 19/19 | 8/8 |
| KIRC | 183/61 | hybrid | FAM245A, PIK3C2G, GPC5, LINC01983, AC104237.2 | 0.993 | 1.000 | 50/50 | 11/11 |
| KIRP | 123/24 | DE | AQP6, UMOD, DDN, HEPACAM2, CRHBP | 1.000 | 1.000 | 29/29 | 8/8 |
| LIHC | 107/39 | DE | PLVAP, COL15A1, GABRD, CDKN3, THBS4 | 0.997 | 1.000 | 26/26 | 11/11 |
| LUAD | 178/49 | DE | PYCR1, FAM83A, ETV4, STX11, OTUD1 | 1.000 | 1.000 | 41/42 | 10/10 |
Cancer Genomics
Cancer genomics uses molecular data to understand tumor biology, identify biomarkers, and guide diagnosis, prognosis, and treatment.
See all 36 papers